指南与共识重症综合管理与镇静镇痛

耐甲氧西林金黄色葡萄球菌监测筛查试验推荐:一项成本最小化分析

Screening test recommendations for methicillin-resistant Staphylococcus aureus surveillance practices: A cost-minimization analysis.
指南 / 共识 · Am J Infect Control · 2017-01-23
一句话结论对全部患者预先隔离的ICU,推荐使用聚合酶链反应筛查试验以最小化总成本;仅隔离MRSA阳性患者的ICU,推荐使用显色琼脂24小时检测以最小化总成本。

该研究采用决策分析计算全面预先隔离与靶向隔离两种监测策略的总成本,并变化筛查试验以找出使不适当成本和总成本最小化的试验。结果显示,全面预先隔离策略下,聚合酶链反应筛查试验总成本最小(每例患者82.51美元),使用传统培养因周转时间更长、隔离成本更高而每例患者多207.60美元。靶向隔离策略下,显色琼脂24小时检测总成本最小(每例患者8.54美元),使用聚合酶链反应每例患者多22.41美元。结论推荐:对所有患者预先隔离的ICU使用聚合酶链反应筛查试验,仅隔离MRSA阳性患者的ICU使用显色琼脂24小时检测,以最小化总成本。

要点

  • 全面预先隔离策略下,聚合酶链反应筛查试验总成本最小,每例患者82.51美元。
  • 全面预先隔离策略下,传统培养因周转时间更长、隔离成本更高,每例患者多207.60美元。
  • 靶向隔离策略下,显色琼脂24小时检测总成本最小,每例患者8.54美元。
  • 靶向隔离策略下,聚合酶链反应每例患者多22.41美元。
  • 作者推荐:对所有患者预先隔离的ICU使用聚合酶链反应筛查试验;仅隔离MRSA阳性患者的ICU使用显色琼脂24小时检测。

适用人群与场景

  • 重症监护病房中接受耐甲氧西林金黄色葡萄球菌监测的住院患者。
  • 采用全面预先隔离策略或仅隔离MRSA阳性患者的靶向隔离策略的重症监护病房。

处置流程与药物剂量

  • 对全部患者预先隔离的重症监护病房,推荐使用聚合酶链反应筛查试验以最小化总成本(每例患者82.51美元)。
  • 仅隔离MRSA阳性患者的重症监护病房,推荐使用显色琼脂24小时检测以最小化总成本(每例患者8.54美元)。

研究设计与关键结果

  • 研究类型为成本最小化分析,采用决策分析计算全面预先隔离与靶向隔离两种监测策略的总成本,并变化筛查试验以识别使不适当成本和总成本最小化的试验,同时进行概率敏感性分析评估输入变化导致的总成本范围。
  • 全面预先隔离策略下,聚合酶链反应筛查试验总成本最小(每例患者82.51美元);使用传统培养因周转时间更长、隔离成本更高,每例患者多207.60美元。
  • 靶向隔离策略下,显色琼脂24小时检测总成本最小(每例患者8.54美元);使用聚合酶链反应每例患者多22.41美元。

证据类型、等级与局限

  • 证据类型:成本最小化分析(决策分析模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于对所有患者实施预先隔离的重症监护病房,作者推荐使用聚合酶链反应筛查试验,因其可通过降低不适当隔离成本来最小化总成本。
  • 对于仅隔离MRSA阳性患者的重症监护病房,作者推荐使用显色琼脂24小时检测以最小化总成本。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: To mitigate methicillin-resistant Staphylococcus aureus (MRSA) infections, intensive care units (ICUs) conduct surveillance through screening patients upon admission followed by adhering to isolation precautions. Two surveillance approaches commonly implemented are universal preemptive isolation and targeted isolation of only MRSA-positive patients.

METHODS: Decision analysis was used to calculate the total cost of universal preemptive isolation and targeted isolation. The screening test used as part of the surveillance practice was varied to identify which screening test minimized inappropriate and total costs. A probabilistic sensitivity analysis was conducted to evaluate the range of total costs resulting from variation in inputs.

RESULTS: The total cost of the universal preemptive isolation surveillance practice was minimized when a polymerase chain reaction screening test was used ($82.51 per patient). Costs were $207.60 more per patient when a conventional culture was used due to the longer turnaround time and thus higher isolation costs. The total cost of the targeted isolation surveillance practice was minimized when chromogenic agar 24-hour testing was used ($8.54 per patient). Costs were $22.41 more per patient when polymerase chain reaction was used.

CONCLUSIONS: For ICUs that preemptively isolate all patients, the use of a polymerase chain reaction screening test is recommended because it can minimize total costs by reducing inappropriate isolation costs. For ICUs that only isolate MRSA-positive patients, the use of chromogenic agar 24-hour testing is recommended to minimize total costs.

来源:Am J Infect Control,查看原文。版权归原作者所有。

参考来源

  1. Whittington MD, Curtis DJ, Atherly AJ, et al. Screening test recommendations for methicillin-resistant Staphylococcus aureus surveillance practices: A cost-minimization analysis. Am J Infect Control. 2017. PMID: 28126259. doi:10.1016/j.ajic.2016.12.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。